n(g),n(g')-dimethyl-l-arginine has been researched along with Obesity in 41 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " ADMA, homocysteine, high sensitive C-reactive protein (hs-CRP) and homeostasis model assessment estimate of insulin resistance (HOMA-IR) were investigated." | 9.15 | Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. ( Aydin, M; Batioglu, S; Erdogan, G; Kilic, S; Yilmaz, N; Zulfikaroglu, E, 2011) |
| "To evaluate retinol-binding protein 4 (RBP4), leptin, and asymmetric dimethylarginine (ADMA) levels in young women with polycystic ovary syndrome (PCOS) and to investigate their relationship with each other and with clinical, metabolic, and hormonal parameters." | 9.15 | Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome. ( Adali, E; Bugdayci, G; Ilhan, GA; Kolusari, A; Yildizhan, B; Yildizhan, R, 2011) |
| "In late-onset asthma phenotype, plasma ratios of L-arginine to ADMA may explain the inverse relationship of BMI to Fe(NO)." | 7.79 | An association between L-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype. ( Bleecker, ER; Busse, WW; Calhoun, WJ; Castro, M; Chung, KF; Comhair, SA; Erzurum, SC; Fitzpatrick, AM; Gaston, B; Hazen, SL; Holguin, F; Israel, E; Jarjour, NN; Khatri, SS; Moore, WC; Peters, SP; Powers, RW; Teague, WG; Wenzel, SE, 2013) |
| "To evaluate the asymmetric dimethylarginine (ADMA) and nitric oxide (NO) levels in obese and lean patients with polycystic ovarian syndrome (PCOS) and find out their relation with hormonal and metabolic parameters." | 7.77 | Evaluation of asymmetric dimethylarginine, nitric oxide levels and associated independent variables in obese and lean patients with polycystic ovarian syndrome. ( Engin-Üstün, Y; Kafkasli, A; Kali, Z; Karabulut, AB; Meydanli, M; Turan, F; Türkçüoğlu, I, 2011) |
| "To evaluate the plasma asymmetric dimethyl arginine (ADMA) levels and carotid intima-media thickness (IMT) in patients with polycystic ovary syndrome (PCOS)." | 7.76 | Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters. ( Ciftci, O; Demirag, NG; Ertugrul, D; Kulaksizoglu, M; Kulaksizoglu, S; Pamuk, BO; Torun, AN; Yildirim, E, 2010) |
| "Asymmetrical dimethylarginine (ADMA) was found to be increased in conditions associated with atherosclerosis and metabolic disorders." | 7.74 | Asymmetric dimethylarginine (ADMA) is tightly correlated with growth in juveniles without correlations to obesity related disorders. ( Almer, G; Gasser, R; Gruber, HJ; Horejsi, R; Mangge, H; März, W; Mayer, C; Meinitzer, A; Möller, R; Pilz, S; Truschnig-Wilders, M, 2008) |
| "The aim of this study was to investigate serum leptin, oxidized low density lipoprotein (ox-LDL) and asymmetric dimethylarginine (ADMA) levels and their interaction with dyslipidaemia in adolescents with polycystic ovary syndrome (PCOS)." | 7.74 | Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. ( Biberoğlu, G; Bideci, A; Camurdan, MO; Cinaz, P; Demirel, F; Hasanoğlu, A; Yesilkaya, E, 2007) |
| "Increased circulating methylarginines (MA) have been linked to the metabolic syndrome to explain endothelial dysfunction and cardiovascular disease risk." | 7.73 | Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. ( Adegoke, OA; Chevalier, S; Gougeon, R; Lamarche, M; Marliss, EB; Morais, JA; Wu, G, 2006) |
| " ADMA, homocysteine, high sensitive C-reactive protein (hs-CRP) and homeostasis model assessment estimate of insulin resistance (HOMA-IR) were investigated." | 5.15 | Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. ( Aydin, M; Batioglu, S; Erdogan, G; Kilic, S; Yilmaz, N; Zulfikaroglu, E, 2011) |
| "This prospective study was performed in order to establish whether improvement of endothelial function after weight reduction can be explained by a decrease of elevated asymmetric dimethyl arginine (ADMA), an inhibitor of endogenous NO-synthase (eNOS)." | 5.15 | Weight loss improves endothelial function independently of ADMA reduction in severe obesity. ( Hildebrand, M; Merle, T; Nawroth, PP; Roeder, E; Rudofsky, G; Wolfrum, C, 2011) |
| "To evaluate retinol-binding protein 4 (RBP4), leptin, and asymmetric dimethylarginine (ADMA) levels in young women with polycystic ovary syndrome (PCOS) and to investigate their relationship with each other and with clinical, metabolic, and hormonal parameters." | 5.15 | Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome. ( Adali, E; Bugdayci, G; Ilhan, GA; Kolusari, A; Yildizhan, B; Yildizhan, R, 2011) |
| "In late-onset asthma phenotype, plasma ratios of L-arginine to ADMA may explain the inverse relationship of BMI to Fe(NO)." | 3.79 | An association between L-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype. ( Bleecker, ER; Busse, WW; Calhoun, WJ; Castro, M; Chung, KF; Comhair, SA; Erzurum, SC; Fitzpatrick, AM; Gaston, B; Hazen, SL; Holguin, F; Israel, E; Jarjour, NN; Khatri, SS; Moore, WC; Peters, SP; Powers, RW; Teague, WG; Wenzel, SE, 2013) |
| "To evaluate the asymmetric dimethylarginine (ADMA) and nitric oxide (NO) levels in obese and lean patients with polycystic ovarian syndrome (PCOS) and find out their relation with hormonal and metabolic parameters." | 3.77 | Evaluation of asymmetric dimethylarginine, nitric oxide levels and associated independent variables in obese and lean patients with polycystic ovarian syndrome. ( Engin-Üstün, Y; Kafkasli, A; Kali, Z; Karabulut, AB; Meydanli, M; Turan, F; Türkçüoğlu, I, 2011) |
| "To evaluate the plasma asymmetric dimethyl arginine (ADMA) levels and carotid intima-media thickness (IMT) in patients with polycystic ovary syndrome (PCOS)." | 3.76 | Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters. ( Ciftci, O; Demirag, NG; Ertugrul, D; Kulaksizoglu, M; Kulaksizoglu, S; Pamuk, BO; Torun, AN; Yildirim, E, 2010) |
| "Asymmetrical dimethylarginine (ADMA) was found to be increased in conditions associated with atherosclerosis and metabolic disorders." | 3.74 | Asymmetric dimethylarginine (ADMA) is tightly correlated with growth in juveniles without correlations to obesity related disorders. ( Almer, G; Gasser, R; Gruber, HJ; Horejsi, R; Mangge, H; März, W; Mayer, C; Meinitzer, A; Möller, R; Pilz, S; Truschnig-Wilders, M, 2008) |
| "The aim of this study was to investigate serum leptin, oxidized low density lipoprotein (ox-LDL) and asymmetric dimethylarginine (ADMA) levels and their interaction with dyslipidaemia in adolescents with polycystic ovary syndrome (PCOS)." | 3.74 | Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. ( Biberoğlu, G; Bideci, A; Camurdan, MO; Cinaz, P; Demirel, F; Hasanoğlu, A; Yesilkaya, E, 2007) |
| " However, it is unknown whether excess weight, insulin resistance, and asymmetric dimethylarginine (ADMA)--an endogenous nitric oxide (NO) synthase inhibitor--also contribute to the vascular changes observed in these patients." | 3.74 | Impaired vascular nitric oxide bioactivity in women with previous gestational diabetes. ( Kautzky-Willer, A; Langenberger, H; Mittermayer, F; Pacini, G; Pleiner, J; Schaller, G; Tura, A; Winzer, C; Wolzt, M, 2007) |
| "This study was performed to test whether plasma asymmetric dimethylarginine (ADMA) concentrations are related to obesity and obesity complications including decrement in insulin sensitivity and adiponectin levels, dyslipidemia and low-grade inflammation." | 3.74 | Unchanged asymmetric dimethylarginine levels in non-diabetic, premenopausal obese women who have common risk factors for cardiovascular disease. ( Bekpinar, S; Can, A; Cetinalp-Demircan, P; Orhan, Y; Unlucerci, Y, 2007) |
| "Increased circulating methylarginines (MA) have been linked to the metabolic syndrome to explain endothelial dysfunction and cardiovascular disease risk." | 3.73 | Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. ( Adegoke, OA; Chevalier, S; Gougeon, R; Lamarche, M; Marliss, EB; Morais, JA; Wu, G, 2006) |
| " The diet was randomly supplemented with keto-amino acids at a dosage of 100 mg/kg BW per day (66 patients, Group I); 65 patients received placebo (Group II)." | 2.73 | Reduction of plasma asymmetric dimethylarginine in obese patients with chronic kidney disease after three years of a low-protein diet supplemented with keto-amino acids: a randomized controlled trial. ( Hanzal, V; Malý, J; Mareckova, O; Racek, J; Schück, O; Stollova, M; Teplan, V, 2008) |
| " NO bioavailability indicates the production and utilization of endothelial NO in organisms, its decrease is related to oxidative stress, lipid infiltration, the expressions of some inflammatory factors and the alteration of vascular tone, which plays an important role in endothelial dysfunction." | 2.58 | Nitric oxide bioavailability dysfunction involves in atherosclerosis. ( Chang, J; Chen, JY; Hong, FF; Wang, XF; Yang, MW; Yang, SL; Ye, ZX; Zhong, HH, 2018) |
| "Asymmetric dimethylarginine (ADMA) is a naturally occurring amino acid that reduces the bioavailability of nitric oxide." | 2.44 | Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. ( Kielstein, JT; Zoccali, C, 2008) |
| " The ADMA-mediated regulation of nitric oxide (NO) production is determined by the quantitative bioavailability of intracellular and extracellular ADMA." | 2.44 | Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism. ( Sim, AS; Wang, J; Wang, XL; Wilcken, DE, 2007) |
| "Obesity is associated with vascular dysfunction." | 1.37 | Exercise-induced alterations of retinal vessel diameters and cardiovascular risk reduction in obesity. ( Drexel, V; Emslander, I; Halle, M; Hanssen, H; Hertel, G; Kotliar, KE; Lorang, D; Nickel, T; Pressler, A; Schmidt-Trucksäss, A; Schuster, T; Sisic, Z; Weis, M, 2011) |
| "It has been reported that estrogen deficiency after menopause might cause a decrement in nitric oxide (NO) bioavailability by increasing the level of asymmetric dimethylarginine (ADMA), a major endogenous nitric oxide synthase inhibitor, thus leading to abnormalities in endothelial function." | 1.37 | Serum asymmetric dimethylarginine and nitric oxide levels in obese postmenopausal women. ( Esin, D; Gurdol, F; Kocak, H; Oner, P; Oner-Iyidogan, Y, 2011) |
| "The prevalence of obesity is increasing in adult and child populations throughout the world." | 1.37 | Favorable effect of short-term lifestyle intervention on human paraoxonase-1 activity and adipokine levels in childhood obesity. ( Bajnok, L; Harangi, M; Józsa, L; Koncsos, P; Nagy, EV; Páll, D; Paragh, G; Seres, I, 2011) |
| "Obesity is associated with an increased risk of developing insulin resistance, hyperinsulinemia, glucose intolerance, dyslipidemia, hypertension, premature atherosclerosis, and coronary artery disease." | 1.36 | Serum asymmetric dimethylarginine levels in normotensive obese individuals. ( Ayhan, S; Demir, K; Erdem, S; Karabag, T; Kaya, A; Kaya, C; Koc, F; Tokac, M; Unlu, A; Vatankulu, MA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (31.71) | 29.6817 |
| 2010's | 28 (68.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holguin, F | 2 |
| Grasemann, H | 1 |
| Sharma, S | 1 |
| Winnica, D | 1 |
| Wasil, K | 1 |
| Smith, V | 1 |
| Cruse, MH | 1 |
| Perez, N | 1 |
| Coleman, E | 1 |
| Scialla, TJ | 1 |
| Que, LG | 1 |
| Chen, JY | 1 |
| Ye, ZX | 1 |
| Wang, XF | 1 |
| Chang, J | 1 |
| Yang, MW | 1 |
| Zhong, HH | 1 |
| Hong, FF | 1 |
| Yang, SL | 1 |
| Yokoro, M | 1 |
| Minami, M | 1 |
| Okada, S | 1 |
| Yano, M | 1 |
| Otaki, N | 1 |
| Ikeda, H | 1 |
| Fukuo, K | 1 |
| Rodrigues-Krause, J | 1 |
| Krause, M | 1 |
| Rocha, IMGD | 1 |
| Umpierre, D | 1 |
| Fayh, APT | 1 |
| Maeda, S | 1 |
| Miyaki, A | 1 |
| Kumagai, H | 1 |
| Eto, M | 1 |
| So, R | 1 |
| Tanaka, K | 1 |
| Ajisaka, R | 1 |
| Ballard, KD | 1 |
| Mah, E | 1 |
| Guo, Y | 1 |
| Pei, R | 1 |
| Volek, JS | 1 |
| Bruno, RS | 1 |
| Egert, S | 1 |
| Baxheinrich, A | 1 |
| Lee-Barkey, YH | 1 |
| Tschoepe, D | 1 |
| Wahrburg, U | 1 |
| Stratmann, B | 1 |
| Teplan, V | 4 |
| Mahrova, A | 1 |
| Piťha, J | 1 |
| Racek, J | 2 |
| Gürlich, R | 1 |
| Valkovsky, I | 1 |
| Stollova, M | 2 |
| Trøseid, M | 1 |
| Nestvold, TK | 1 |
| Nielsen, EW | 1 |
| Thoresen, H | 1 |
| Seljeflot, I | 2 |
| Lappegård, KT | 1 |
| İn, E | 1 |
| Özdemir, C | 1 |
| Kaman, D | 1 |
| Sökücü, SN | 1 |
| Amarasekera, AT | 1 |
| Sverdlov, AL | 1 |
| Horowitz, JD | 1 |
| Ngo, DT | 1 |
| Gruber, HJ | 1 |
| Mayer, C | 1 |
| Meinitzer, A | 1 |
| Almer, G | 1 |
| Horejsi, R | 1 |
| Möller, R | 1 |
| Pilz, S | 1 |
| März, W | 1 |
| Gasser, R | 1 |
| Truschnig-Wilders, M | 1 |
| Mangge, H | 1 |
| Schück, O | 1 |
| Mareckova, O | 1 |
| Hanzal, V | 1 |
| Malý, J | 1 |
| Lieb, W | 1 |
| Benndorf, RA | 2 |
| Benjamin, EJ | 1 |
| Sullivan, LM | 1 |
| Maas, R | 1 |
| Xanthakis, V | 1 |
| Schwedhelm, E | 1 |
| Aragam, J | 1 |
| Schulze, F | 2 |
| Böger, RH | 2 |
| Vasan, RS | 1 |
| Kielstein, JT | 1 |
| Zoccali, C | 1 |
| Pamuk, BO | 1 |
| Torun, AN | 1 |
| Kulaksizoglu, M | 1 |
| Ertugrul, D | 1 |
| Ciftci, O | 1 |
| Kulaksizoglu, S | 1 |
| Yildirim, E | 1 |
| Demirag, NG | 1 |
| Türkçüoğlu, I | 1 |
| Engin-Üstün, Y | 1 |
| Turan, F | 1 |
| Kali, Z | 1 |
| Karabulut, AB | 1 |
| Meydanli, M | 1 |
| Kafkasli, A | 1 |
| Koc, F | 1 |
| Tokac, M | 1 |
| Erdem, S | 1 |
| Kaya, C | 1 |
| Unlu, A | 1 |
| Karabag, T | 1 |
| Vatankulu, MA | 1 |
| Demir, K | 1 |
| Ayhan, S | 1 |
| Kaya, A | 1 |
| Kilic, S | 1 |
| Yilmaz, N | 1 |
| Zulfikaroglu, E | 1 |
| Erdogan, G | 1 |
| Aydin, M | 1 |
| Batioglu, S | 1 |
| Siervo, M | 2 |
| Corander, M | 1 |
| Mander, AP | 1 |
| Browning, LM | 1 |
| Jebb, SA | 1 |
| Rudofsky, G | 1 |
| Roeder, E | 1 |
| Merle, T | 1 |
| Hildebrand, M | 1 |
| Nawroth, PP | 1 |
| Wolfrum, C | 1 |
| Hanssen, H | 1 |
| Nickel, T | 1 |
| Drexel, V | 1 |
| Hertel, G | 1 |
| Emslander, I | 1 |
| Sisic, Z | 1 |
| Lorang, D | 1 |
| Schuster, T | 1 |
| Kotliar, KE | 1 |
| Pressler, A | 1 |
| Schmidt-Trucksäss, A | 1 |
| Weis, M | 1 |
| Halle, M | 1 |
| Engeli, S | 1 |
| Tsikas, D | 1 |
| Lehmann, AC | 1 |
| Böhnke, J | 1 |
| Haas, V | 1 |
| Strauß, A | 1 |
| Janke, J | 1 |
| Gorzelniak, K | 1 |
| Luft, FC | 1 |
| Jordan, J | 1 |
| Kocak, H | 1 |
| Oner-Iyidogan, Y | 1 |
| Gurdol, F | 1 |
| Oner, P | 1 |
| Esin, D | 1 |
| Yildizhan, R | 1 |
| Ilhan, GA | 1 |
| Yildizhan, B | 1 |
| Kolusari, A | 2 |
| Adali, E | 1 |
| Bugdayci, G | 1 |
| Li Volti, G | 1 |
| Salomone, S | 1 |
| Sorrenti, V | 1 |
| Mangiameli, A | 1 |
| Urso, V | 1 |
| Siarkos, I | 1 |
| Galvano, F | 1 |
| Salamone, F | 1 |
| Koncsos, P | 1 |
| Seres, I | 1 |
| Harangi, M | 1 |
| Páll, D | 1 |
| Józsa, L | 1 |
| Bajnok, L | 1 |
| Nagy, EV | 1 |
| Paragh, G | 1 |
| Bluck, LJ | 1 |
| Bayrak, T | 1 |
| Dursun, P | 1 |
| Bayrak, A | 1 |
| Gültekin, M | 1 |
| Cakır, E | 1 |
| Ozyurt, M | 1 |
| Zeyneloğlu, HB | 1 |
| Huang, F | 1 |
| del-Río-Navarro, BE | 1 |
| Pérez Ontiveros, JA | 1 |
| Ruiz-Bedolla, E | 1 |
| Navarro-Olivos, E | 1 |
| Villafaña, S | 1 |
| Bravo, G | 1 |
| Hong, E | 1 |
| Comhair, SA | 1 |
| Hazen, SL | 1 |
| Powers, RW | 1 |
| Khatri, SS | 1 |
| Bleecker, ER | 1 |
| Busse, WW | 1 |
| Calhoun, WJ | 1 |
| Castro, M | 1 |
| Fitzpatrick, AM | 1 |
| Gaston, B | 1 |
| Israel, E | 1 |
| Jarjour, NN | 1 |
| Moore, WC | 1 |
| Peters, SP | 1 |
| Teague, WG | 1 |
| Chung, KF | 1 |
| Erzurum, SC | 1 |
| Wenzel, SE | 1 |
| Sterk, PJ | 1 |
| Ricciardolo, FL | 1 |
| Eid, HM | 1 |
| Arnesen, H | 1 |
| Hjerkinn, EM | 1 |
| Lyberg, T | 1 |
| Marliss, EB | 1 |
| Chevalier, S | 1 |
| Gougeon, R | 1 |
| Morais, JA | 1 |
| Lamarche, M | 1 |
| Adegoke, OA | 1 |
| Wu, G | 1 |
| Demirel, F | 1 |
| Bideci, A | 1 |
| Cinaz, P | 1 |
| Camurdan, MO | 1 |
| Biberoğlu, G | 1 |
| Yesilkaya, E | 1 |
| Hasanoğlu, A | 1 |
| Wilcken, DE | 1 |
| Sim, AS | 1 |
| Wang, J | 1 |
| Wang, XL | 1 |
| Onat, A | 1 |
| Hergenç, G | 1 |
| Pleiner, J | 1 |
| Mittermayer, F | 1 |
| Langenberger, H | 1 |
| Winzer, C | 1 |
| Schaller, G | 1 |
| Pacini, G | 1 |
| Kautzky-Willer, A | 1 |
| Tura, A | 1 |
| Wolzt, M | 1 |
| Cetinalp-Demircan, P | 1 |
| Can, A | 1 |
| Bekpinar, S | 1 |
| Unlucerci, Y | 1 |
| Orhan, Y | 1 |
| Reimann, M | 1 |
| Schutte, AE | 1 |
| Malan, NT | 1 |
| Schwarz, PE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics[NCT01715844] | Phase 1 | 10 participants (Actual) | Interventional | 2013-09-07 | Completed | ||
| Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Fat[NCT02482610] | 22 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Milk[NCT02482675] | 23 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| Vasoprotective Activities of Low-Fat Milk in Individuals With Metabolic Syndrome[NCT01411293] | 21 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| Study for the Investigation of New Individual Risk Profiles and Therapeutic Strategies in Obesity Related Cardiovascular and Metabolic Disorders.[NCT00482924] | 1,500 participants (Anticipated) | Observational | 2003-01-31 | Recruiting | |||
| Exercise, Arterial Cross-Talk Modulation and Inflammation in an Ageing Population (ExAMIN AGE)[NCT02796976] | 158 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Adiposity and Airway Inflammation in HIV-Associated Airway Disease[NCT02975258] | 102 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Biomarker of nitric oxide homeostasis is based on the assessment of total nitrite and nitrate concentrations. Changes relative to baseline were used to calculate area under the curve of total nitric oxide metabolites from 0-180 min, i.e. Area Under the Curve (AUC) of change from baseline in nitric oxide homeostasis from 0 min to 180 min (i.e., AUC (NOx 0 min- 0 min, NOx 30 min-0 min, NOx 60 min-0 min, etc) (NCT02482610)
Timeframe: Area under curve of nitrite/nitrate for three hours (0, 30, 60, 90, 120, 150, and 180 min)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | -2229 |
| Glucose With Whole Fat Milk | -1240 |
| Glucose With Non-fat Milk | -1221 |
Glucose concentrations evaluated on the basis as change from baseline to calculate glucose area under the curve from 0-180 min, i.e. Area Under the Curve (AUC) of change from baseline in glucose from 0 min to 180 min (i.e., AUC (glucose 0 min- 0 min, glucose 30 min-0 min, glucose 60 min-0 min, etc) (NCT02482610)
Timeframe: Area under curve of glucose for three hours (0, 30, 60, 90, 120, 150, and 180 min)
| Intervention | mg/dL*min (Mean) |
|---|---|
| Glucose | 6259 |
| Glucose With Whole Fat Milk | 4481 |
| Glucose With Non-fat Milk | 3408 |
MDA concentrations evaluated on the basis as change from baseline to calculate MDAarea under the curve from 0-180 min, i.e. Area Under the Curve (AUC) of change from baseline in MDA from 0 min to 180 min (i.e., AUC (MDA 0 min- 0 min, MDA 30 min-0 min, MDA 60 min-0 min, etc) (NCT02482610)
Timeframe: Area under curve of MDA for three hours (0, 30, 60, 90, 120, 150, 180 min)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | 54.9 |
| Glucose With Whole Fat Milk | 25.78 |
| Glucose With Non-fat Milk | 31.3 |
Flow mediated dilation (FMD) evaluated on the basis as change from baseline to calculate FMD area under the curve from 0-180 min, i.e. i.e. Area Under the Curve (AUC) of change from baseline in FMD from 0 min to 180 min (i.e., AUC (FMD 0 min- 0 min, FMD 30 min-0 min, FMD 60 min-0 min, etc) (NCT02482610)
Timeframe: Area under curve of FMD for three hours (0, 30, 60, 90, 120, 150, and 180 min)
| Intervention | %*min (Mean) |
|---|---|
| Glucose | -195.9 |
| Glucose With Whole Fat Milk | -6.181 |
| Glucose With Non-fat Milk | -5.629 |
Plasma 8-isoprostaglandin-F2a concentration, calculated as 8-isoprostaglandin-F2a AUC from 0-180 minutes (NCT02482675)
Timeframe: 8-isoprostaglandin-F2a area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | pg/mL*min (Mean) |
|---|---|
| Glucose | 2162.2 |
| Glucose With Non-fat Milk | -824.14 |
| Glucose With Whey Protein Isolate | -18.75 |
| Glucose With Sodium Caseinate | 229.14 |
Plasma 8-isoprostaglandin-F2a/Arachidonic acid concentration, calculated as 8-isoprostaglandin-F2a/Arachidonic acid AUC from 0-180 minutes (NCT02482675)
Timeframe: 8-isoprostaglandin-F2a/Arachidonic acid area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | (pg/mL)/(ug/mL)*min (Mean) |
|---|---|
| Glucose | 10129 |
| Glucose With Non-fat Milk | -1655.2 |
| Glucose With Whey Protein Isolate | 2422.3 |
| Glucose With Sodium Caseinate | 3907.6 |
Arachidonic acid concentration, calculated as Arachidonic acid AUC from 0-180 minutes (NCT02482675)
Timeframe: Arachidonic acid area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | ug/mL*min (Mean) |
|---|---|
| Glucose | -2570 |
| Glucose With Non-fat Milk | -1358.4 |
| Glucose With Whey Protein Isolate | -2762.6 |
| Glucose With Sodium Caseinate | -2752.0 |
Plasma arginine concentration, calculated as ARG AUC from 0-180 minutes (NCT02482675)
Timeframe: ARG area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | -3922 |
| Glucose With Non-fat Milk | -1235 |
| Glucose With Whey Protein Isolate | 195 |
| Glucose With Sodium Caseinate | -189 |
Plasma ADMA/arginine concentration, calculated as ADMA/ARG AUC from 0-180 minutes (NCT02482675)
Timeframe: ADMA/ARG area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | (nmol/L)/(umol/L)*min (Mean) |
|---|---|
| Glucose | 275 |
| Glucose With Non-fat Milk | 55 |
| Glucose With Whey Protein Isolate | 47 |
| Glucose With Sodium Caseinate | 25 |
Plasma CCK concentration, calculated as CCK AUC from 0-180 minutes (NCT02482675)
Timeframe: CCK area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | pmol/L*min (Mean) |
|---|---|
| Glucose | 89.67 |
| Glucose With Non-fat Milk | 422.87 |
| Glucose With Whey Protein Isolate | 352.5 |
| Glucose With Sodium Caseinate | 519.94 |
Plasma insulin concentration, calculated as insulin AUC from 0-180 minutes (NCT02482675)
Timeframe: Insulin area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | uIU/mL*min (Mean) |
|---|---|
| Glucose | 8179.7 |
| Glucose With Non-fat Milk | 8196.1 |
| Glucose With Whey Protein Isolate | 8654.6 |
| Glucose With Sodium Caseinate | 8656.9 |
Plasma MDA measured as MDA AUC from 0-180 minutes (NCT02482675)
Timeframe: Area under curve for MDA for three hours (0, 30, 60, 90, 120, 150, 180 min.) (change from baseline)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | 66.5 |
| Glucose With Non-fat Milk | 43.2 |
| Glucose With Whey Protein Isolate | 46.4 |
| Glucose With Sodium Caseinate | 45.1 |
NOx AUC for 0-180 minutes (NCT02482675)
Timeframe: Area under curve for nitrite/nitrate for three hours (0, 30, 60, 90, 120, 180 min) (change from baseline)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | -1363 |
| Glucose With Non-fat Milk | 347 |
| Glucose With Whey Protein Isolate | -21 |
| Glucose With Sodium Caseinate | -57.2 |
Plasma glucose concentration from 0-180 minutes (NCT02482675)
Timeframe: Area under the curve for glucose for three hours (0, 30, 60, 90, 120, 180 minutes) (change from baseline)
| Intervention | mg/dL*min (Mean) |
|---|---|
| Glucose | 5828 |
| Glucose With Non-fat Milk | 4032 |
| Glucose With Whey Protein Isolate | 3340 |
| Glucose With Sodium Caseinate | 3640 |
Plasma SDMA/arginine concentration, calculated as SDMA/ARG AUC from 0-180 minutes (NCT02482675)
Timeframe: SDMA/ARG area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | (nmol/L)/(umol/L)*min (Mean) |
|---|---|
| Glucose | 175 |
| Glucose With Non-fat Milk | 31 |
| Glucose With Whey Protein Isolate | 4 |
| Glucose With Sodium Caseinate | -17 |
Plasma BH4/BH2 concentration, calculated as BH4/BH2 AUC from 0-180 minutes (NCT02482675)
Timeframe: Plasma BH4/BH2 concentration area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | ratio*min (Mean) |
|---|---|
| Glucose | -47 |
| Glucose With Non-fat Milk | 78 |
| Glucose With Whey Protein Isolate | 171 |
| Glucose With Sodium Caseinate | 131 |
Flow mediated dilation (FMD) of the brachial artery, calculated as FMD AUC for 0-180 minutes (change from baseline) (NCT02482675)
Timeframe: Area under curve for FMD for three hours (0, 30, 60, 90, 120, 180 minutes)
| Intervention | %*min (Mean) |
|---|---|
| Glucose | -307 |
| Glucose With Non-fat Milk | -34.8 |
| Glucose With Whey Protein Isolate | -36.8 |
| Glucose With Sodium Caseinate | -110 |
4 reviews available for n(g),n(g')-dimethyl-l-arginine and Obesity
| Article | Year |
|---|---|
Nitric oxide bioavailability dysfunction involves in atherosclerosis.
Topics: Animals; Arginine; Atherosclerosis; Biological Availability; Cardiovascular Diseases; Endothelium, V | 2018 |
Association of l-Arginine Supplementation with Markers of Endothelial Function in Patients with Cardiovascular or Metabolic Disorders: A Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Arginine; Cardiovascular Diseases; Diabetes Mellitus; Dietary Supplements; Endothelium, | 2018 |
Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease.
Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Chronic Disease; Disease Progression; Genetic Therap | 2008 |
Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism.
Topics: Arginine; Citrulline; Dietary Supplements; Hepatocytes; Homocysteine; Humans; Kidney Diseases; Liver | 2007 |
9 trials available for n(g),n(g')-dimethyl-l-arginine and Obesity
| Article | Year |
|---|---|
L-Citrulline increases nitric oxide and improves control in obese asthmatics.
Topics: Adult; Aged; Arginine; Asthma; Citrulline; Dietary Supplements; Female; Forced Expiratory Volume; Hu | 2019 |
Lifestyle modification decreases arterial stiffness and plasma asymmetric dimethylarginine level in overweight and obese men.
Topics: Adult; Animals; Ankle Brachial Index; Arginine; Biomarkers; Caloric Restriction; Cardiovascular Dise | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Effects of an energy-restricted diet rich in plant-derived α-linolenic acid on systemic inflammation and endothelial function in overweight-to-obese patients with metabolic syndrome traits.
Topics: Adipokines; Adult; alpha-Linolenic Acid; Arginine; Biomarkers; C-Reactive Protein; Chitinase-3-Like | 2014 |
Reduction of plasma asymmetric dimethylarginine in obese patients with chronic kidney disease after three years of a low-protein diet supplemented with keto-amino acids: a randomized controlled trial.
Topics: Adult; Aged; Amino Acids; Arginine; Combined Modality Therapy; Diet, Protein-Restricted; Dietary Sup | 2008 |
Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment.
Topics: Adult; Arginine; Body Mass Index; Cardiovascular Diseases; Contraceptives, Oral; Female; Homocystein | 2011 |
Weight loss improves endothelial function independently of ADMA reduction in severe obesity.
Topics: Adolescent; Adult; Aged; Arginine; Body Mass Index; Caloric Restriction; Cell Adhesion Molecules; En | 2011 |
Influence of dietary fat ingestion on asymmetrical dimethylarginine in lean and obese human subjects.
Topics: Adult; Arginine; Chromatography, Gas; Cross-Over Studies; Diet; Dietary Fats; Eating; Energy Intake; | 2012 |
Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome.
Topics: Adult; Arginine; Biomarkers; Female; Humans; Leptin; Obesity; Polycystic Ovary Syndrome; Prospective | 2011 |
28 other studies available for n(g),n(g')-dimethyl-l-arginine and Obesity
| Article | Year |
|---|---|
Urinary sodium-to-potassium ratio and serum asymmetric dimethylarginine levels in patients with type 2 diabetes.
Topics: Adult; Aged, 80 and over; Arginine; Blood Pressure; Carotid Intima-Media Thickness; Cross-Sectional | 2018 |
Early exercise training after renal transplantation and asymmetric dimethylarginine: the effect of obesity.
Topics: Adult; Aged; Anthropometry; Arginine; Blood Pressure; Cohort Studies; Exercise Therapy; Female; Glyc | 2014 |
Soluble CD14 is associated with markers of vascular dysfunction in bariatric surgery patients.
Topics: Adipose Tissue; Adult; Age Factors; Arginine; Bariatric Surgery; Biomarkers; Female; Humans; Lipopol | 2015 |
Heat Shock Proteins, L-Arginine, and Asymmetric Dimethylarginine Levels in Patients With Obstructive Sleep Apnea Syndrome.
Topics: Adult; Aged; Arginine; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus; Disease Susceptibilit | 2015 |
Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations in obese diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Diabetes Mellitus; Female; Humans; Linear Models; Male; Mi | 2016 |
Asymmetric dimethylarginine (ADMA) is tightly correlated with growth in juveniles without correlations to obesity related disorders.
Topics: Adolescent; Alkaline Phosphatase; Arginine; Atherosclerosis; Blood Pressure; Body Mass Index; Child; | 2008 |
Plasma asymmetric dimethylarginine, L-arginine and left ventricular structure and function in a community-based sample.
Topics: Aged; Arginine; Female; Heart Atria; Heart Ventricles; Humans; Linear Models; Male; Middle Aged; Mul | 2009 |
Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters.
Topics: Adolescent; Adult; Arginine; Energy Metabolism; Female; Humans; Obesity; Polycystic Ovary Syndrome; | 2010 |
Effect of keto acids on asymmetric dimethylarginine, muscle, and fat tissue in chronic kidney disease and after kidney transplantation.
Topics: Adipose Tissue; Adult; Aged; Amino Acids; Arginine; Body Mass Index; Diet, Protein-Restricted; Human | 2009 |
Evaluation of asymmetric dimethylarginine, nitric oxide levels and associated independent variables in obese and lean patients with polycystic ovarian syndrome.
Topics: Adolescent; Adult; Arginine; Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Female | 2011 |
Serum asymmetric dimethylarginine levels in normotensive obese individuals.
Topics: Adult; Arginine; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Enzyme Inhibitors; Humans | 2010 |
Acute effects of hyperglycaemia on asymmetric dimethylarginine (ADMA), adiponectin and inflammatory markers (IL-6, hs-CRP) in overweight and obese women with metabolic syndrome.
Topics: Adiponectin; Adult; Aged; Arginine; Biomarkers; Female; Humans; Hyperglycemia; Interleukin-6; Metabo | 2010 |
Exercise-induced alterations of retinal vessel diameters and cardiovascular risk reduction in obesity.
Topics: Adult; Arginine; Athletes; Cardiovascular Diseases; Enzyme-Linked Immunosorbent Assay; Exercise; Hum | 2011 |
Serum asymmetric dimethylarginine and nitric oxide levels in obese postmenopausal women.
Topics: Adiponectin; Aged; Aged, 80 and over; Anthropometry; Arginine; Body Mass Index; Female; Ghrelin; Hum | 2011 |
Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice.
Topics: Acetylcholine; Animals; Antioxidants; Aorta; Arginine; Diabetes Mellitus; Disease Models, Animal; En | 2011 |
Favorable effect of short-term lifestyle intervention on human paraoxonase-1 activity and adipokine levels in childhood obesity.
Topics: Adipokines; Adiponectin; Adolescent; Arginine; Aryldialkylphosphatase; Body Mass Index; Child; Diet; | 2011 |
In vivo nitric oxide synthesis, insulin sensitivity, and asymmetric dimethylarginine in obese subjects without and with metabolic syndrome.
Topics: Adult; Arginine; Blood Glucose; Blood Pressure; Cholesterol, HDL; Female; Glucose Tolerance Test; Hu | 2012 |
Paraoxonase lactonase activity (PON-HTLase), asymmetric dimethylarginine (ADMA) and platelet activating factor-acetylhydrolase (PAF-AH) activity in non-obese women with PCOS.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adolescent; Adult; Arginine; Aryldialkylphosphatase; | 2012 |
Changes in ghrelin and asymmetrical dimethylarginine in obese Mexican adolescents after six-month lifestyle intervention.
Topics: Adolescent; Arginine; Body Mass Index; Child; Eating; Feeding Behavior; Female; Ghrelin; Humans; Ins | 2013 |
An association between L-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype.
Topics: Adolescent; Adult; Age of Onset; Aged; Arginine; Asthma; Body Mass Index; Cross-Sectional Studies; F | 2013 |
Clinical-biological phenotyping beyond inflammation in asthma delivers.
Topics: Age of Onset; Arginine; Asthma; Humans; Obesity | 2013 |
Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine.
Topics: Aged; Arginine; Arteriosclerosis; Coronary Disease; Cross-Sectional Studies; Enzyme Inhibitors; Huma | 2004 |
Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover.
Topics: Adult; Aged; Aged, 80 and over; Aging; Arginine; Blood Glucose; Body Composition; Female; Glucose; G | 2006 |
Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome.
Topics: Adolescent; Apolipoproteins B; Arginine; Biomarkers; Case-Control Studies; Cholesterol; Cholesterol, | 2007 |
Reduced asymmetric dimethylarginine (ADMA) levels mediate in the protection from metabolic syndrome by smoking.
Topics: Arginine; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Smoking | 2008 |
Impaired vascular nitric oxide bioactivity in women with previous gestational diabetes.
Topics: Adult; Arginine; Body Mass Index; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diabetic Angiopa | 2007 |
Unchanged asymmetric dimethylarginine levels in non-diabetic, premenopausal obese women who have common risk factors for cardiovascular disease.
Topics: Adult; Arginine; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Case-Control Studies; Fem | 2007 |
Asymmetric dimethylarginine is associated with parameters of glucose metabolism in Caucasian but not in African women from South Africa.
Topics: Adult; Arginine; Black People; Body Mass Index; C-Reactive Protein; Cross-Sectional Studies; Fatty A | 2007 |